Amy is a UK and European patent attorney who specialises in securing and defending complex biotechnology patents, with a focus on advanced therapeutics. She has particular expertise in therapeutic antibodies, non-standard antibody formats, cell therapy, CAR-T technologies, delivery systems and discovery platforms.
Clients turn to Amy for clear, strategic guidance in technically demanding areas of patent law. She has a strong track record in complex prosecution and has played a key role in the successful defence of several biologics patents before the European Patent Office.
Before joining Kilburn & Strode in 2021, Amy trained and practised at another leading IP firm. Today, she advises clients ranging from academic founders and venture-backed start-ups to global life sciences companies, offering insight that reflects both technical depth and commercial acumen.
Amy holds a BSc and PhD in Neuroscience from University College London. Her doctoral research explored the links between neural network dysfunction and deregulated gene expression in neurodevelopmental disorders, with experimental work spanning molecular biology, genetics, pharmacology and electrophysiology.
Her PhD had a strong interdisciplinary focus, combining laboratory research with computational analysis. This continues to shape her interest in the convergence of biotechnology and emerging technologies, particularly data-driven approaches to early-stage discovery. She has carried out research in both the UK and Germany and brings a hands-on understanding of translational science to her IP practice.